← Back to Search

Immunotherapy

CCW702 for Prostate Cancer

Phase 1

Waitlist Available

Led By Mark Markowski, MD

Research Sponsored by Calibr, a division of Scripps Research

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a new immunotherapy drug for prostate cancer. The goal is to find the maximum tolerated dose and to assess the safety and effectiveness of the drug.

Eligible Conditions

Metastatic Castration Resistant Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Part 1a and 1b: Assess the safety and tolerability of CCW702, including incidence of dose limiting toxicities

Part 1a and 1b: Select recommended phase/part 2 dose

Part 2: to assess clinical efficacy at the RP2D

Trial Design

3Treatment groups

Experimental Treatment

Group I: Part 2: Dose ExpansionExperimental Treatment1 Intervention

CCW702 administered subcutaneously Q7D at RP2D.

Group II: Part 1b: Dose Escalation Q7DExperimental Treatment1 Intervention

CCW702 administered subcutaneously Q7D, dose escalating cohorts.

Group III: Part 1a: Dose Escalation QODExperimental Treatment1 Intervention

CCW702 administered subcutaneously QOD, dose escalating cohorts.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Calibr, a division of Scripps ResearchLead Sponsor

5 Previous Clinical Trials

235 Total Patients Enrolled

Mark Markowski, MDPrincipal InvestigatorJohns Hopkins University Hospital - Sidney Kimmel Comprehensive Cancer Center

1 Previous Clinical Trials

30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is CCW702 likely to create any health risks for individuals?

"Due to the preliminary nature of this trial, Power assigned CCW702 a score of 1 on its safety scale. There is only limited data concerning both efficacy and safety at present."

Answered by AI

Is there still availability for test subjects in this experiment?

"According to clinicaltrials.gov, the posted date of this medical trial is July 17th 2020 and it was last updated on September 29th 2022; thus, no more patients are being sought at present. However, there are 1968 other trials actively searching for individuals who would like to participate in research studies."

Answered by AI

How widespread is the implementation of this experiment?

"The clinical trial has 6 locations, such as University of Virginia in Charlottesville, the University of California at San Diego and Karmanos Cancer Institute in Detroit, with additional sites available."

Answered by AI

Recent research and studies

Proceedings of the National Academy of SciencesJournal

Bispecific Small Molecule–antibody Conjugate Targeting Prostate Cancer

Kim, Chan Hyuk, Jun Y. Axup, Brian R. Lawson, Hwayoung Yun, Virginie Tardif, Sei Hyun Choi, Quan Zhou, et al.. 2013. “Bispecific Small Molecule–antibody Conjugate Targeting Prostate Cancer”. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1316026110.

Science AdvancesJournal

A Psma-targeted Bispecific Antibody for Prostate Cancer Driven by a Small-molecule Targeting Ligand

Lee, Sung Chang, Jennifer S. Y. Ma, Min Soo Kim, Eduardo Laborda, Sei-Hyun Choi, Eric N. Hampton, Hwayoung Yun, et al.. 2021. “A Psma-targeted Bispecific Antibody for Prostate Cancer Driven by a Small-molecule Targeting Ligand”. Science Advances. American Association for the Advancement of Science (AAAS). doi:10.1126/sciadv.abi8193.

clinicaltrials.govStudy

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

2020. "First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04077021.